To combat emerging coronaviruses, developing safe and efficient platforms to evaluate viral 21 protease activities and the efficacy of protease inhibitors is a high priority. Here we exploit a 22
biosafety level 2 (BSL-2) chimeric Sindbis virus system to evaluate protease activities and the 23 efficacy of inhibitors directed against the papain-like protease (PLpro) of Severe Acute 24
Respiratory Syndrome coronavirus (SARS-CoV), a biosafety level 3 (BSL-3) pathogen. We 25 engineered Sindbis virus to co-express PLpro and a substrate, murine interferon stimulated 26 gene 15 (ISG15), and found that PLpro mediates removal of ISG15 (deISGylation) from 27 cellular proteins. Mutation of the catalytic cysteine residue of PLpro or addition of a PLpro 28 inhibitor blocked deISGylation in virus-infected cells. Thus, deISGylation is a marker of PLpro 29 activity. Infection of Interferon-alpha/beta receptor knockout (IFNAR -/-) mice with these 30 chimeric viruses revealed that PLpro deISGylation activity removed the ISG15-mediated 31 protection during viral infection. Importantly, administration of a PLpro inhibitor protected 32 these mice from lethal infection demonstrating the efficacy of a coronavirus protease inhibitor 33 in a mouse model. However, this PLpro inhibitor was not sufficient to protect mice from lethal 34 infection with SARS-CoV MA15, suggesting that further optimization of the delivery and 35 stability of PLpro inhibitors is needed. We extended the chimeric virus platform to evaluate 36 papain-like protease/deISGylating activity of Middle East Respiratory Syndrome Coronavirus 37 (MERS-CoV), to provide a small animal model to evaluate PLpro protease inhibitors to this 38 recently emerged pathogen. This platform has the potential to be universally adaptable to 39 other viral and cellular enzymes that have deISGylating activity. 40 such as Middle East Respiratory Syndrome Coronavirus. This system provides an important 48 tool to rapidly assess the efficacy of protease inhibitors targeting existing and emerging 49
Introduction 52
Emerging coronaviruses (CoVs) are now recognized for their life-threatening potential. 53
The outbreak of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) that occurred 54 a decade ago resulted in over 8000 infected people with 10% mortality (1). A recently 55 emerged coronavirus, designated Middle East Respiratory Syndrome coronavirus 56 (MERS-CoV), has infected over 837 people, with 291 deaths as of July 24, 2014 (2) . 57
Epidemiologic studies implicate animal reservoirs as the source for emerging coronaviruses. 58
By identifying a SARS-like CoV from Chinese horseshoe bats and analyzing the mutations in 59 the spike glycoprotein, first in intermediate hosts and then in humans, researchers were able 60 to document the evolution of an emerging CoV (3). The footprint for the evolution of 61 MERS-CoV is not yet clear. MERS-CoV has about 80% genome sequence identity to the bat 62 coronaviruses HKU4 and HKU5 (4, 5). In addition, infectious MERS-CoV has been isolated 63 from the respiratory tract of young camels (6-8) and there is accumulating evidence that adult 64 camels have specific antibodies to MERS-CoV, consistent with endemic infection in the camel 65 population (9, 10). Currently, it is unclear if the human cases of MERS are from sporadic 66 introduction from animal reservoirs with limited human to human transmission or if there is 67 ongoing transmission of MERS-CoV in asymptomatic humans or intermediate hosts (11) (12) (13) . 68
It is clear that CoVs have zoonotic potential for crossing the species-barrier and emerging into 69 the human population to cause lethal disease. 70 Viral proteases are logical targets for antiviral drug development, and protease inhibitors 71 have been identified to block the papain-like protease (PLpro) domain of SARS-CoV (14) . 72 5 PLpro is encoded in the viral replicase polyprotein and is critical for processing the polyprotein 73 to generate a functional replicase complex. Structural and enzymatic studies revealed that 74
PLpro is also a viral deubiquitinase (DUB), which can cleave ubiquitin (Ub) or ubiquitin-like 75 molecules, such as interferon stimulated gene 15 (ISG15), from substrate proteins (15) (16) (17) . 76
Moreover, the catalysis-dependent interferon antagonism of PLpro implies that it may be 77 involved in evading host innate immunity (18, 19) . High-throughput screening efforts led to the 78 identification of small molecule inhibitors directed against the viral papain-like protease 79 domain, and synthetic medicinal chemistry and structure-activity relationship studies have 80 produced compounds that inhibit replication of SARS-CoV in cell culture (14, 20) . However, 81 one of the challenges for preclinical, antiviral drug development is the availability of a small 82 animal model for emerging CoVs. For SARS-CoV, infection of mouse-adapted strains in mice 83 (21, 22) or transgenic mice expressing the receptor (Angiotensin-converting enzyme 2, ACE2) 84 (23, 24), may serve as model systems for evaluating the efficacy of therapeutics. However, 85 these studies must be performed in biosafety level 3 laboratories (BSL-3) with select agent 86 status. For MERS-CoV, although rhesus macaques can be infected (25, 26) , less expensive 87 animal models such as mice and hamster are not susceptible to natural infection (27, 28 The goal of our study was to develop a biosafety level 2 system to evaluate inhibitors of 96 the papain-like proteases of highly pathogenic emerging coronaviruses such as SARS-CoV 97 and MERS-CoV. We were inspired by the fundamental work of Frias-Stahli et al., who first 98 demonstrated that a chimeric Sindbis virus system could be used to evaluate the potential 99 protease activity of a BSL-4 pathogen, Crimean Congo Hemorrhagic Fever virus (36). This 100 chimeric virus system is based on the use of the positive-strand RNA virus, Sindbis virus (SV), 101 a BSL-2 pathogen that is rapidly cleared by the immune system after infection in mice. 102
Lenschow and co-workers showed that the interferon response, particularly interferon 103 stimulated gene 15 (ISG15), is critical for efficient clearance of SV (35). Consequently, SV 104 infection of interferon receptor knockout mice (IFNR -/-), which are unable to signal the 105 induction of interferon stimulated genes, results in a lethal infection. However, if the gene for 106 ISG15 is inserted into and expressed by SV, then infection with the chimeric virus induces an 107 antiviral state and mice are protected from lethal infection. To induce the antiviral state, 108 ISG15 must be conjugated to host cell proteins, a process termed ISGylation (40). The 109 removal of ISG15 by deISGylating enzymes such as the L protease of CCHFV results in the 110 abrogation of the protection mediated by ISG15 and mice succumb to infection. Thus, 111 deISGylating enzymes can be used to "toggle off" the effect of ISG15 in this system. Given 112 that the PLpros of CoVs not only function to process the viral polyprotein but also possess 113 deISGylating activity (15, 37), we reasoned that the chimeric Sindbis-ISG15-Protease (SIP) epitope tag was codon-optimized, synthesized, and subcloned into the pUC57 vector 144 (Genscript, NJ). A catalytically inactive mutant of PLpro (cysteine 1651 to alanine) was 145 generated as described previously (19) by site-directed mutagenesis PCR using primers 146 (available upon request).The DNAs of interest were cut from recombinant pUC57 plasmids 147 and cloned into the TE12Q vector, and designated SIP-SWT and SIP-SMT, respectively. 148 2) SIP-MWT and SIP-MMT. A DNA sequence comprising of ISG15-IRES-PLpro (amino 149 acids1483-1802 in pp1a of MERS-CoV, accession number AFS88944) was generated by 150 two-step overlapping PCR using primers (available upon request).Briefly, the fragment of 151 ISG15-IRES was amplified from the recombinant pUC57 plasmid described above, and the 152 fragment of MERS-CoV PLpro or its catalytic mutant in frame with V5 epitope was amplified 153 from the plasmids of pcDNA-MERS-PLpro or its catalytic mutant (cysteine 1592 to alanine), 154
respectively. The fragment of ISG15-IRES-PLpro was generated by PCR amplification using 155 primers (available upon request) and cloned into the BstE II restriction site of the TE12Q 156 9 vector, and designated SIP-MWT and SIP-MMT, respectively. 157
All constructs were verified by sequencing and linearized by digestion with Xho I 158 restriction enzyme. The viral RNA was synthesized by in vitro transcription reaction following 159 the manufacturer's instructions (Ambion) and the RNA was subsequently electroporated into 160 the BHK-21 cells with 3 pulses at conditions of 850V, 25μF in a 0.4cm cuvette cap (Bio-Rad). 161 Viral supernatants were harvested at 16~24 hours (hrs) post electroporation and the titers 162 were determined by standard plaque assay on the BHK-21 cells. 163
Western blotting. Cell lysates were separated in a 10% SDS-PAGE gel and transferred to 164 PVDF membrane in transfer buffer (25mM Tris, 192mM glycine, 20% methanol) for 1 hr at 165 65V. The membrane was blocked using 5% dried skim milk in TBST buffer (0.9% NaCl, 10mM 166
Tris-HCl, pH7.5, 0.1% Tween 20) for 2 hrs at room temperature and subsequently incubated 167 with primary antibodies for overnight at 4℃. The mouse anti-myc tag monoclonal antibody 168 (MBL) was used to detect the myc-ISG15 and the ISGylated proteins. ISG15 was detected 169 using rabbit anti-ISG15 polyclonal antibodies (kind gift of the Lenschow lab). The expression 170 of PLpro and β-actin were detected using mouse anti-V5 (Invitrogen) and anti-beta actin 171 (Ambion) monoclonal antibodies, respectively. HRP-conjugated goat-anti mouse (Southern 172
Biotech) was used as the secondary antibody and detected by using Western Lighting 173
Chemiluminescence Reagent Plus (PerkinElmer) and visualized using a FluoroChem E 174
Imager. 175
Viral growth kinetics. To analyze the replication of SIP viruses, the viral growth kinetics 176 assays were performed. Briefly, 10 5 BHK-21 cells per well in 24-well plate were infected with MERS-CoV were generated, and named as SIP-SWT, SIP-SMT, SIP-MWT, and SIP-MMT, 233 respectively (Fig. 1A) . The expression of ISG15 and PLpro was detected by immunoblotting 234 lysates prepared from virus-infected cells (Fig. 1B) . Analysis of viral growth kinetics revealed 235 that the four SIP viruses replicate with similar kinetics and to high titer in BHK-21 cells (Fig.  236   1C) . Furthermore, these viruses were stable upon passage in BHK-21 cells, which was in 237 contrast to chimeric viruses containing larger insertions that had an EMCV IRES (Data not 238 shown). whether PLpros expressed from Sindbis virus is able to cleave ISG15, BHK-21 cells were 241 transfected with plasmids expressing ISGylation substrates and enzymes (myc tagged ISG15, 242
Ube1L, UbcH8, and Herc5) and subsequently infected with SIP-WT or SIP-MT viruses. 243
Western blot results show that cellular proteins were ISGylated in mock-infected cells 244 transfected with ISGylation machinery plasmids. In contrast, the level of ISGylated proteins 245 was significantly reduced in cells infected with SIP-WT but not SIP-MT viruses (Fig.2) . The 246 decreased level of ISGylated proteins in SIP-WT infected cells is not due to virus induced cell 247 death or lack of host translation in the context of a Sindbis virus infection as the SIP-MT grows 248 to similar levels as the SIP-WT (Fig. 1C) exhibiting greater than 25% weight loss were humanely euthanized in accordance with animal 258 care guidelines. As expected, the mice infected with SIP-SWT virus lost more body weight 259 14 than mice infected with SIP-SMT virus at day 2~5 post infection (d.p.i) (Fig. 3A) . SIP-SWT 260 infection results in over 80% mortality, which is significantly higher than the mortality observed 261 in mice infected with the SIP-SMT virus (26.7%) (P=0.0005; Fig. 3B ). Moreover, we found the 262 SIP virus expressing wild-type PLpro from MERS-CoV (SIP-MWT), but not catalytic inactive 263 cysteine mutant of MERS-CoV PLpro (SIP-MMT) is able to inhibit the ISG15 function. The 264 weight loss at 4~5 d.p.i and the mortality of mice infected with SIP-MWT were significant more 265 than those of SIP-MMT infected-mice ( Fig. 3C and 3D) . These results indicate that PLpros of 266
SARS-CoV and MERS-CoV are capable of disrupting the ISG15-mediated protection in 267
IFNAR -/mice, suggesting its role in antagonizing the innate immune response. In our system, 268 the SIP virus infected-mice approached the maximum weight loss at 5~6 d.p.i and then either 269 (14, 20) . We recently designed and evaluated the 278 biological activity of a second-generation of SARS-CoV PLpro inhibitors in vitro (39). One of 279 15 these compounds, 3e, inhibits SARS-CoV PLpro with a potency of 390 nM and has an 280 antiviral potency of 8.3 μM against SARS-CoV in Vero-E6 cells. Importantly, this compound is 281 not cytotoxic, does not bind to human serum albumin and has increased metabolic stability 282 compared to other compounds evaluated (39) . Therefore, to determine if compound 3e 283 blocked PLpro activity in the context of the chimeric SIP virus, we exploited the deISGylation 284 assay in cell culture. We found that the cells treated with compound 3e, but not the control 285 compound 3h (Fig. 4A) , a structural homolog of 3e with a higher IC 50 (600 nM) and no antiviral 286 activity (39), showed an increase in the level of ISGylated proteins in SIP-WT virus-infected 287 cells (Fig. 4B ). This indicates that the deISGylating activity of PLpro was blocked by 288 compound 3e. We also found that the deISGylating activity of PLpro was inhibited by 289 compound 3e in a dose-dependent manner (data not shown). To assess the specificity of 290 compound 3e, we tested the activity of a cellular deISGylating enzyme USP18 (also known as 291 Ubp43) in the presence of 3e. Western blot results revealed that the level of ISGylated 292 proteins in USP18-transfected cells was significantly decreased compared to the control; and 293 there was no observable change in level of ISGylation in the transfected cells treated with 294 compound 3e (Fig. 4C ). This result indicates that compound 3e does not inhibit the 295 deISGylating activity of USP18. Taken together, these results suggest that compound 3e 296 specifically blocks SARS-CoV PLpro deISGylating activity in cell culture during replication of 297 the SIP virus. 298
SARS-CoV PLpro protease inhibitor 3e protects mice from lethal SIP virus infection.
To 299 16 determine whether the PLpro inhibitor was effective in a small animal model, we injected 300 IFNAR -/mice subcutaneously with SIP-WT and administered intraperitoneally (i.p.) 301 compound 3e (50μg/dose) at 0 and 2 d.p.i. Although we found there is no significant weight 302 loss between 3e and vehicle treated mice at early time points except at 5 d.p.i. (P<0.01), the 303 majority of the 3e treated-mice (64.7%) recovered from infection before approaching the 304 weight loss of euthanasia. In contrast, SIP-WT infected mice administered the vehicle control 305 exhibited significantly higher mortality (31.6% survival rate, P=0.021; Fig. 5 ). The effect of 306 compound 3e was specific to SARS-CoV PLpro activity as it had no significant effect on the 307 pathogenesis of Sindbis virus infection of IFNAR -/mice and there was no evidence of weight 308 loss in mice injected with the compound 3e alone (data not shown). These results 309 demonstrate the protective effect of compound 3e during SIP-WT virus infection. and the virus titers on Day 4 showed significant reduction in virus replication, compared to 320 untreated virus control (Fig. 6) . The results suggest that although protease inhibitor 3e was 321 capable of protecting the majority of mice from lethal systemic SIP virus infection, the inhibitor 322 is either not sufficiently stable or bioavailable in the respiratory tract to reduce the replication 323 and pathogenesis of a respiratory tract infection with SARS-CoV MA15 in mice. 324
Discussion 325
This work establishes a chimeric Sindbis virus-mouse model system for assessing 326 deISGylating activity of SARS-CoV and MERS-CoV PLpros and for evaluating SARS-CoV 327
PLpro inhibitors in BSL-2 containment. To develop this model system, we exploited a chimeric 328
Sindbis system pioneered by Frias-Staheli and coworkers who first showed that viral 329 proteases with deISGylating activity could remove the protective antiviral state induced by 330 ISG15 (36). We extended their studies by: 1) modifying the chimeric virus to express either 331
SARS-CoV PLpro or MERS-CoV PLpro under translational control of the HCV-IRES, this 332
shortened IRES enabled insertion of larger CoV USP-like proteases; and 2) showing that 333 SARS-CoV PLpro inhibitors could be evaluated in SIP virus-infected IFNAR -/mice. This is the 334 first demonstration of the efficacy and specificity of an inhibitor that targets a viral papain-like 335 cysteine protease (PLpro) in a virus-infected animal. This is important because there are over 336 100 cellular DUBS and previously it was unclear if the PLpro inhibitor was sufficiently specific 337 to alter protease/deISGylating activity in an infected animal. In general, this chimeric 338 Sindbis-protease system enables the study of enzymes with deISGylating activity, and 339 18 establishes a BSL-2 model that can be used to evaluate the efficacy of small molecule 340 inhibitors to existing and emerging coronaviruses in vivo. 341
We hypothesize that the multifunctionality of CoV PLpros as proteases, deubiquitinating 342 and deISGylating enzymes is important in viral pathogenesis, especially in antagonizing the 343 innate immune response. ISG15 functions as an antiviral molecule through ISGylation of host 344 substrates and by eliciting cytokine activity (39). Mice lacking ISG15 are more susceptible to 345 lethal infection with Sindbis virus, herpesvirus and influenza virus (35, 41) . The role of ISG15 346 in CoV pathogenesis is not yet clear. Ma and co-workers showed that murine coronavirus 347 infection of USP18-deficient mice, where ISGylation levels are high, resulted in lower viral 348 titers and prolonged survival compared to wild type mice, suggesting that high levels of 349
ISGylation may delay CoV replication and pathogenesis (42). However, USP18 also mediates 350
ISGylation-independent dendritic cells maturation (43), thus the loss of USP18 function may 351 affect the kinetics of the immune response to viral infection. In the present study, we directly 352
shown that CoV PLpros are capable of disrupting the protective effect of ISG15 in vivo, 353 suggesting that PLpros have evolved an ISGylation antagonism mechanism to promote viral 354
replication. 355
A major advantage of the SIP virus system is that we were able to study the PLpros of 356 pathogenic CoVs in mice in a BSL-2 environment. This is particularly important because of 357 the limited number of small animal models currently available for the study of 31 it is a very sensitive system for evaluating protease inhibitors and we demonstrate efficacy of 374 protease inhibitor 3e, which was previously shown to block replication of SARS-CoV in cell 375 culture (39). However, as we report here, protease inhibitors must also be evaluated in the 376 context of a respiratory tract infection, such as with mouse adapted-SARS-CoV-MA15 (21, 377 22). We found that protease inhibitor 3e was not effective at blocking replication and 378 HCoV-229E and HCoV-OC43. HCoV-NL63 generally causes mild upper respiratory disease in 390 adult but it can cause more severe respiratory disease in young children (46, 47) . 391
HCoV-HKU1 has been associated with pneumonia in the elderly (48). Currently there are no 392 animal models for evaluating inhibitors to HCoV-NL63 or HCoV-HKU1. Other PLPs including 393 those of bat coronaviruses are speculated to act as deISGylating enzymes as well since they 394 share conserved catalytic elements and are predicted to recognize similar cleavage sites in 395 the viral polyprotein. We are currently developing SIP viruses expressing the PLP2 domain of 396
HCoV-NL63 and other CoVs with the long term goal of identifying broad spectrum PLpro 397 inhibitors that could block replication of existing and emerging coronaviruses. Ube1L, UbcH8, and Herc5) and subsequently infected with SIP viruses as indicated. Cells 595 lysate were probed with anti-myc to detect ISGylated proteins and unconjugated ISG15. The 596 expression of PLpro and beta-actin as a loading control were detected with anti-V5 and 597 anti-beta actin antibodies, respectively. 598 
